Clinical Trial Detail

NCT ID NCT02323191
Title A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Hoffmann-La Roche
Indications

stomach cancer

urinary bladder cancer

Her2-receptor negative breast cancer

ovarian cancer

sarcoma

Therapies

Atezolizumab

LY3022855

Age Groups: adult

Additional content available in CKB BOOST